Results of the unadjusted, partially adjusted and fully adjusted models to assess the HR of exposures in lymphoma development in patients with systemic lupus erythematosus (SLE)
| Variable | Unadjusted HR (95% CI) | Partially adjusted model (95% CI) | Fully adjusted HR (95% CI) |
|---|---|---|---|
| Outside North America | 0.81 (0.46 to 1.45) | – | 0.91 (0.44 to 1.90) |
| Calendar year | 1.02 (0.99 to 1.04) | – | 0.99 (0.96 to 1.02) |
| Male | 2.74 (1.45 to 5.19) | 2.64 (1.39 to 5.02) | 2.70 (1.38 to 5.28) |
| Age | 1.04 (1.03 to 1.06) | 1.04 (1.02 to 1.06) | 1.04 (1.02 to 1.06) |
| White race/ethnicity | 1.11 (0.67 to 1.84) | – | 0.91 (0.53 to 1.56) |
| Sjogren's syndrome | 2.08 (1.13 to 3.8) | 1.94 (1.04 to 3.61) | 1.79 (0.88 to 3.62) |
| Glucocorticosteroids ever used | 1.69 (0.95 to 3.03) | – | 0.79 (0.25 to 2.45) |
| Cumulative glucocorticosteroids >3.5 g* | 1.82 (1.06 to 3.14) | 1.94 (1.11 to 3.39) | 2.57 (0.94 to 7.04) |
| Cyclophosphamide ever used | 2.07 (1.13 to 3.81) | 1.90 (1.02 to 3.53) | 2.80 (0.87 to 8.98) |
| Cumulative cyclophosphamide >6 g | 1.68 (0.80 to 3.55) | – | 0.68 (0.18 to 2.59) |
| Azathioprine (AZA) ever used | 0.72 (0.41 to 1.27) | – | 0.84 (0.32 to 2.25) |
| Cumulative AZA >36.5 g | 0.55 (0.27 to 1.11) | – | 0.59 (0.18 to 1.92) |
| Methotrexate ever used | 1.06 (0.50 to 2.26) | – | 0.74 (0.31 to 1.78) |
| Mycophenolate ever used | 1.47 (0.61 to 3.54) | – | 1.47 (0.58 to 3.71) |
| Antimalarial drugs ever used | 1.63 (0.94 to 2.84) | – | 1.55 (0.81 to 2.96) |
| High disease activity† | 0.62 (0.34 to 1.13) | 0.65 (0.35 to 1.22) | 0.68 (0.36 to 1.29) |
*Systemic glucocorticosteroids, considered in prednisone equivalent doses.
†Defined as Mean Adjusted SLE Disease Activity Index-2K (SLEDAI-2K) value of 6 or more. For centres using alternative disease activity measures, high activity was defined as the highest quartile of the mean adjusted activity scores.